CalciMedica (CALC) Retained Earnings (2019 - 2026)
CalciMedica's (CALC) quarterly Retained Earnings came in at -$184.4 million in Q1 2026, down 18439900.0% YoY from N/an in Q1 2025, and up 2.6% on a QoQ basis from -$189.3 million in Q4 2025.
CalciMedica (CALC) Retained Earnings (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Retained Earnings data on file, last reported at -$184.4 million in Q1 2026.
- Quarterly Retained Earnings fell 18439900.0% year-over-year to -$184.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184.4 million (down 18439900.0% YoY) and the FY2025 annual result came in at -$189.3 million, down 18.5% from the prior year.
- Retained Earnings improved to -$184.4 million in Q1 2026, from -$189.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$1000.0 in Q1 2025 to a low of -$189.3 million in Q4 2025.
- A 5-year average of -$139.4 million and a median of -$149.9 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings soared 100.0% — and 2026, when it plunged 18439900.0%.
- Tracing CALC's Retained Earnings over 5 years: stood at -$111.7 million in 2022, then plunged by 30.76% to -$146.1 million in 2023, then declined by 9.38% to -$159.8 million in 2024, then retreated by 18.5% to -$189.3 million in 2025, then climbed by 2.6% to -$184.4 million in 2026.
- The last three Retained Earnings figures came in at -$184.4 million (Q1 2026), -$189.3 million (Q4 2025), and -$178.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | CalciMedica | 9.97 Mn | -8.65 Mn | - | -192.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -192.00 Mn |
| Mar 31, 2026 | -184.40 Mn |
| Dec 31, 2025 | -189.33 Mn |
| Sep 30, 2025 | -178.57 Mn |
| Jun 30, 2025 | -170.80 Mn |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -159.76 Mn |
| Sep 30, 2024 | -155.51 Mn |
| Jun 30, 2024 | -149.89 Mn |
| Mar 31, 2024 | -145.90 Mn |
| Dec 31, 2023 | -146.06 Mn |
| Sep 30, 2023 | -141.90 Mn |
| Jun 30, 2023 | -137.30 Mn |
| Mar 31, 2023 | -131.00 Mn |
| Dec 31, 2022 | -111.71 Mn |
| Sep 30, 2022 | -123,000.00 |
| Jun 30, 2022 | -187.58 Mn |
| Mar 31, 2022 | -179.30 Mn |
| Dec 31, 2021 | -169.19 Mn |
| Sep 30, 2021 | -160.51 Mn |